(Reuters) -Czech generic drugmaker Zentiva said on Thursday that private equity group Advent International had agreed to sell the company to rival GTCR for an undisclosed value.
The Financial Times had first reported the deal on Wednesday, saying it was worth 4.1 billion euros ($4.80 billion).
($1 = 0.8540 euros)
(Reporting by Unnamalai L in Bengaluru; Editing by Maju Samuel)
Brought to you by www.srnnews.com
